Core Insights - Crystal Tech Holdings (02228) successfully executed a textbook "lightning placement," showcasing its strong market appeal and efficient execution in capital markets [1] - The company raised HKD 2.65 billion through the placement of approximately 286 million shares, with a placement price of HKD 9.28 per share, reflecting a premium of about 75.8% over the IPO price and 23.4% over the average closing price of the last 30 trading days [1] - The placement attracted significant interest from various institutional investors, including the world's largest sovereign fund, Norges Bank Investment Management, indicating strong confidence in the company's growth prospects [2] Financial Performance - In the first half of 2025, Crystal Tech Holdings achieved its first large-scale profitability, with revenue from drug discovery solutions increasing by 615.2% to HKD 435 million, and revenue from intelligent robotics solutions rising by 95.9% to HKD 82 million [2] - As of August 27, the company's market capitalization exceeded HKD 41.2 billion, making it the highest-valued company in the Asian AI drug discovery sector [2] Cash Reserves - As of June 30, 2025, the company held cash reserves of HKD 5.308 billion, and with the new financing, total cash reserves are approximately HKD 8 billion, providing a strong financial foundation for continued leadership in the field [3] Innovation and Future Plans - The company plans to utilize the funds from the placement for product and research iteration, commercialization expansion, and potential mergers and acquisitions, while also exploring innovative financial tools such as RWA (Real World Assets) and RDA (Real Data Assets) [1][4] - The recent launch of the RWA registration platform in Hong Kong aligns with the company's strategy to digitize real-world assets, enhancing liquidity and broadening financing channels for innovative drug development [4]
“AI for Science第一股”晶泰控股(02228)完成近30亿港元新股配售融资 登顶全球AI制药融资王